John Koreth

John Koreth

Hematology | Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 30, 2026

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Journal: Transplantation and cellular therapy
Published: April 28, 2026

Extensive Oral Ulcerations After Stem Cell Transplant.

Extensive Oral Ulcerations After Stem Cell Transplant.

Journal: JAMA oncology
Published: March 12, 2026

New age GVHD prophylaxis regimens: what works for what donor and why.

New age GVHD prophylaxis regimens: what works for what donor and why.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.

Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Journal: Transplantation and cellular therapy
Published: November 22, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances
Published: September 16, 2025

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Journal: Blood advances
Published: September 16, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances
Published: August 19, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances
Published: August 19, 2025

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Journal: Blood advances
Published: August 05, 2025

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Journal: Blood advances
Published: August 05, 2025
Showing 1-12 of 166

Last Updated: 09/26/2026